Reports to VAERS of drug ineffectiveness/vaccine inefficacy by immune status among HIV-positive persons, 1990–2016.

<p>Reports to VAERS of drug ineffectiveness/vaccine inefficacy by immune status among HIV-positive persons, 1990–2016.</p

Characteristics of reports to VAERS among HIV-positive persons, 1990–2016.

<p>Characteristics of reports to VAERS among HIV-positive persons, 1990–2016.</p

Supplementary materials: Assessment of second primary malignancies among treated and untreated patients with chronic lymphocytic leukemia using real-world data from the USA

These are peer-reviewed supplementary figures and tables for the article 'Treatment patterns and economic burden of bacterial vaginosis among commercially insured women in the USA' published in the Journal of Comparative Effectiveness Research.Supplementary Figure 1: Timing of events for the treated and untreated subgroupsSupplementary Figure 2: The covariate balance between the treated and untreated subgroupsSupplementary Table 1: Procedure and NDC codes for CLL treatmentsSupplementary Table 2: Diagnosis codes for SPMsAim: Improved management of chronic lymphocytic leukemia (CLL) has resulted in a growing populationof CLL survivors; these patients have a higher risk of developing second primary malignancies (SPMs) versusthe general population. This retrospective cohort study aims to assess the timing, frequency, incidence andtypes of SPMs in treated and untreated patients with CLL in the USA, using the Surveillance, Epidemiology,and End Results (SEER) Medicare database, which links a nationally representative cancer registry withMedicare claims data. Patients & methods: Patients aged ≥66 years with newly diagnosed CLL between1 January 2010 and 31 December 2016, who were enrolled in Parts A and B of Medicare for ≥12 monthspre-diagnosis of CLL were selected from the database. Patients were assessed for ≥36 months until the endof continuous enrollment in Medicare Parts A, B and D, a switch to a health maintenance organization,death, or end of the study period (December 2019). Results: Of 3053 patients included in the analyses,620 (20.3%) were treated and 2433 (79.7%) were untreated within 36 months of diagnosis. Overall,638 (20.9%) patients developed a SPM, 26.8% of patients in the treated cohort and 19.4% of patientsin the untreated cohort. The most common SPMs for both cohorts were squamous cell carcinoma andacute myeloid leukemia. Among the 166 treated patients who developed a SPM, a greater proportiondeveloped their first SPM after treatment initiation versus those who developed their first SPM priorto treatment initiation (p therapy developed a SPM (p Findings indicate that treatment type and timing can affect SPM development in patients with CLL.Combined with previous findings, this can help inform best practices in monitoring for SPM in patientswith CLL.</p

Additional file 1: Appendix A. of A scoping review on the conduct and reporting of scoping reviews

– MEDLINE search strategy: contains the complete search strategy for the MEDLINE database; designed and carried out by an information specialist. Appendix B - References to Included Studies. Appendix C - Word cloud of methodology cited. Appendix D - Components listed in the research objectives: provides a thematic summary of research objectives reported by authors. Appendix E - Components listed in the conceptual definitions: contains the main components listed in the conceptual or working definitions of a “scoping review” from the included scoping reviews, along with frequency (i.e. count/proportion) information. Appendix F - Agreement between the definition of a scoping review and the research objective(s): provides an overall comparison between research objectives reported and the definition of a scoping review based on the thematic analysis. Appendix G - Types of sources searched for grey literature. Appendix H - Joanna Briggs Institute Methodology Assessment: An assessment of the methodology of the 494 included scoping reviews relative to each of the steps recommended by the Joanna Briggs Institute guidance on scoping reviews. Appendix I - Description of key components of knowledge translation (KT) activities: contains a brief description of the main components of the knowledge translation activities from the included scoping reviews, by category of KT (i.e. integrated KT, end of grant KT, integrated and end of grant KT). (DOCX 802 kb

Additional file 1: of Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis

Protocol (PDF 121 kb